Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
AlmirallShare is Almirall’s open innovation platform, positioned as a collaboration gateway for connecting global scientific partners and advancing innovation in skin health. Its core purpose is not general workplace collaboration, but to identify differentiated products and innovative solutions in strategic therapeutic areas of dermatology, with the goal of improving quality of life for patients with skin diseases.
Based on the captured text, the platform includes sections such as About us, Collaboration Opportunities, What we offer, In numbers, News, FAQs, Contact us, and Login, and it supports email subscriptions for news and events. The platform emphasizes running collaboration projects with global partners in a “structured, agile, and transparent” way, but it does not disclose specific details on project management, file sharing, data rooms, approval workflows, permission controls, or member collaboration. As such, it looks more like a pharmaceutical open innovation and BD collaboration portal than a mature enterprise SaaS collaboration suite.
The page does not provide plans, pricing, a free version, or trial information, nor does it mention payment methods. Third-party integrations, APIs, developer support, and self-hosted deployment are also not mentioned in the text. On security and compliance, the site only confirms the existence of Terms of use, Privacy Policy, and Cookies Policy, and requires users to accept the terms and privacy policy when subscribing to the newsletter. However, it does not disclose encryption, audit features, certifications, or life sciences industry compliance capabilities.
The main advantage is its clear domain focus: it is designed for dermatology innovation collaboration and is suitable for researchers, universities/research institutions, biopharma companies, and potential technology partners looking to understand collaboration opportunities with Almirall. The downside is that public product information is limited, the SaaS aspect is weak, and it lacks explanations of key enterprise procurement concerns such as pricing, permissions, security, integrations, and service support.
Access from China cannot be determined from the text alone. If a China-based team wants to pursue cross-border pharmaceutical collaboration, it should further verify website accessibility, English-language communication, compliance material submission requirements, and whether domestic payment or contract workflows are supported. Alternatives may include open innovation platforms such as Inpart, Halo, Wellspring, and NineSigma, as well as local pharmaceutical BD, research project management, and enterprise collaboration tools.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on almirallshare.com official site.
almirallshare.com is an Spain SaaS provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Workable. Click "Visit Official Site" to reach almirallshare.com directly.